secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001104659-23-024939
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager closes Neurocrine collaboration, receives $175M; Neurocrine CSO joins board
--------------------------------------------------------------------------------

- Collaboration Agreement effective; Neurocrine pays $136M upfront.
- Neurocrine buys 4,395,588 shares at $8.88/share for ~$39M.
- Jude Onyia, Ph.D., Neurocrine's CSO, appointed to board effective closing.
- Onyia designated Class III director until 2024 annual meeting; Neurocrine retains nomination right while holding ≥10%.
- Onyia receives standard non-employee director compensation: $40K cash retainer, initial option for 44,000 shares, annual option for 22,000 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923024939/0001104659-23-024939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465923024939/tm237527d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-024939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer